Study procedures
| Clinical data collected | Blood samples |
| Date of birth | FBC |
| Age at time of assessment | Liver enzymes (albumin, bilirubin, ALT, ALP) |
| Sex at birth | AST |
| Ethnicity | GGT |
| Weight | HbA1c |
| Height | FIB-4 score |
| BMI | Lipids |
| Waist and Hip circumference | ELF |
| Blood pressure | PRO-C3 |
| AUDIT score33 | Blood for storage to assess future novel biomarkers of liver disease |
| Current alcohol consumption (average units/week over last year) | |
| History of previous heavy alcohol consumption (>35 U/week for females or >50 U/week for males) for >1 year | |
| Smoking history | |
| Relevant medical history including: hypertension, T2DM, dyslipidaemia, obstructive sleep apnoea | |
| Current medications | |
| EQ-5D-L questionnaire34 |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUDIT, Alcohol Use Disorders Identification Tool; ELF, enhanced liver fibrosis test; EQ-5D-L, EuroQol-5 Dimensions-Level; FBC, full blood count; GGT, gamma glutamyl transferase; T2DM, type 2 diabetes.